We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+22.96%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.54B
AUM Growth
+$187M
Cap. Flow
-$12.7M
Cap. Flow %
-0.82%
Top 10 Hldgs %
46.64%
Holding
69
New
11
Increased
6
Reduced
41
Closed
4

Top Buys

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$42M
2
ZGNX
Zogenix, Inc.
ZGNX
+$25.5M
3
TSRO
TESARO, Inc.
TSRO
+$24.7M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$14.8M
5
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$12.1M

Top Sells

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$18.2M
2
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$15.1M
3
QTRX icon
Quanterix
QTRX
+$12.5M
4
BPMC
Blueprint Medicines
BPMC
+$11.8M
5
MTVA
MetaVia Inc
MTVA
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 86.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
1
AnaptysBio
ANAB
$1.54B
$113M 7.36%
1,135,000
-98,422
-8% -$8.17M
MRTX
2
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$85.3M 5.54%
1,810,000
-108,350
-6% -$6.03M
NKTR icon
3
Nektar Therapeutics
NKTR
$2.39B
$83.5M 5.43%
91,333
-8,667
-9% -$7.4M
NKTR icon
4
CALL
Nektar Therapeutics
NKTR
$2.39B
$81M 5.26%
88,560
-33,333
-27% -$28.5M
TECX
5
Tectonic Therapeutic
TECX
$536M
$77.4M 5.03%
124,399
-1,250
-1% -$554K
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$74.2M 4.82%
4,172,498
-140,000
-3% -$2.59M
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$54.3M 3.53%
3,556,669
-44,285
-1% -$645K
RETA
8
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$54M 3.51%
660,000
+210,000
+47% +$14.8M
TSRO
9
DELISTED
TESARO, Inc.
TSRO
$48.8M 3.17%
1,250,000
+700,000
+127% +$24.7M
IFRX icon
10
InflaRx
IFRX
$243M
$46M 2.99%
1,341,540
-145,725
-10% -$4.7M
MYOK
11
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$45.6M 2.97%
700,000
-67,363
-9% -$3.96M
PRNB
12
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$43.4M 2.82%
+1,486,898
New +$42M
AUTL
13
Autolus Therapeutics
AUTL
$389M
$40.7M 2.64%
1,326,136
-199,451
-13% -$5.38M
RCKT icon
14
Rocket Pharmaceuticals
RCKT
$343M
$36.9M 2.4%
1,500,659
-19,231
-1% -$417K
QTNT
15
DELISTED
Quotient Limited Ordinary Shares
QTNT
$36.6M 2.38%
121,250
+13,979
+13% +$4.2M
TBPH icon
16
Theravance Biopharma
TBPH
$873M
$35.9M 2.34%
1,100,000
-200,000
-15% -$5.45M
GTHX
17
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$33.5M 2.18%
640,481
-79,504
-11% -$4.34M
KZR
18
DELISTED
Kezar Life Sciences
KZR
$33.2M 2.16%
155,291
-2,000
-1% -$349K
SLDB icon
19
Solid Biosciences
SLDB
$792M
$31.6M 2.06%
44,701
-1,029
-2% -$646K
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$29.7M 1.93%
380,000
-170,000
-31% -$11.8M
OMER icon
21
CALL
Omeros
OMER
$845M
$27.8M 1.8%
1,136,900
+167,900
+17% +$3.74M
SAGE
22
DELISTED
Sage Therapeutics
SAGE
$26.8M 1.74%
190,000
-49,619
-21% -$7.66M
ASND icon
23
Ascendis Pharma A/S
ASND
$16.5B
$24.8M 1.61%
350,000
-21,739
-6% -$1.5M
ZGNX
24
DELISTED
Zogenix, Inc.
ZGNX
$24.8M 1.61%
+500,000
New +$25.5M
OMER icon
25
Omeros
OMER
$845M
$24.4M 1.59%
1,000,000
-314,118
-24% -$7.01M
1
2 3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2018 Portfolio in Review

As of Q3 2018, Cormorant Asset Management held 69 positions worth $1.54B, up 14% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q3 2018 filing shows 11 new, 6 increased, 41 reduced and 4 closed positions. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,486,898 shares worth $43.4M. The largest sale was Vanda Pharmaceuticals, an estimated $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier.

  • Cormorant Asset Management's largest Q3 2018 buy was Principia Biopharma Inc. Common Stock: 1,486,898 shares worth $43.4M.
  • Cormorant Asset Management added most to TESARO, Inc. in Q3 2018, an estimated $24.7M increase.
  • Cormorant Asset Management's biggest Q3 2018 reduction was Spectrum Pharmaceuticals Inc, cutting an estimated $15.1M.
  • Cormorant Asset Management fully exited Vanda Pharmaceuticals in Q3 2018, selling an estimated $18.2M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2018.
  • Cormorant Asset Management opened 11 new positions and closed 4 in Q3 2018.
  • Cormorant Asset Management's portfolio value rose 14% quarter-over-quarter to $1.54B.

Based on Cormorant Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.